Simplifying Global Compliance
FDA Looks to Boost Industry Competition Through Deregulation
International Pharmaceutical Regulatory Monitor
The FDA is using President Trump’s mandate to shrink the size of the government’s regulatory footprint as an opportunity to re-examine how its rules may be misused to delay generic competition — and to clear the decks of older regulations that advances in science have made obsolete, a senior HHS official told lawmakers.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing